Egalet Ltd. is a specialty pharmaceutical company using its patented technology to produce novel therapeutics on its own and with partners. Based on the proprietary technology, Egalet is developing a pipeline of tamper-resistant opioids that are nearing pivotal testing. In addition, Egalet has collaborations with pharmaceutical and biotechnology companies in the initial phase of clinical testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet. In addition, the Egalet® technology, a novel, patented drug delivery platform, was designed to resist tampering, to prevent easy extraction and to deter the abuse of medications via known routes of abuse, including chewing, snorting, and injecting. The technology offers a predictable and tailored pharmacokinetic profile, lacks a significant food effect and alcohol dose dumping, and can be used with a broad range of opioids and non-opioids. Egalet has extensively filed patents to protect its inventions covering both the technology and product-specific patents.